# TOVX earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/TOVX) · [Earnings tab](https://www.lopjlb.com/stock/TOVX?tab=earnings) Updated: 2026-08-12T05:32:10 Quarters analyzed: 8 ## Cross-quarter narrative Across eight quarterly updates Theriva Biologics (formerly Synthetic Biologics) has steadily extended its cash runway from a 2023 endpoint in early 2021 to Q1 2025 by the latest call, reflecting successful capital management but still flagging financing pressure beyond that horizon. Clinical execution remains the core focus: the VCN‑01 pancreatic cancer (VIRAGE) trial stays on‑track, while investigator‑sponsored brain‑tumor studies in Leeds have slipped due to UK staffing and protocol delays. Regulatory uncertainty is a constant thread, with repeated mentions of pending FDA feedback for retinoblastoma and IND timing for VCN‑11, and occasional country‑specific queries (e.g., Germany). Manufacturing scale‑up for VCN‑01 and albumin‑shield candidates is repeatedly cited as a risk but shows no clear resolution. Partnership and out‑licensing discussions surface intermittently, yet no concrete deals materialize. Data readouts are pushed further out, now expected in 2025, heightening outcome uncertainty. Overall, the company’s narrative shifts from early acquisition integration and trial initiation to prolonged execution timelines, extended financing needs, and persistent regulatory and operational risks. ## Latest CallCard · Q4 Theriva Biologics reports on‑track enrollment for its VCN‑01 VIRAGE trial, delayed IND filing for retinoblastoma, on‑track SYN‑004 cohort, and cash runway into Q1 2025, while highlighting safety feasibility of repeated dosing. **Guidance:** maintained — Management indicated they remain on track to meet enrollment milestones and have cash runway into Q1 2025, with no change to prior guidance. **Tone:** mgmt 0.8 · Q&A pressure 0.4 · divergence 0.3 Prepared remarks emphasized steady progress, on‑track milestones and sufficient cash runway, indicating optimism. ### Demand visibility Management provided clear timelines for trial enrollments and data readouts. VIRAGE enrollment to finish H1 2024, SYN‑004 cohort Q2 2024, retinoblastoma follow‑up mid‑2024 with IND expected 2024‑25. ### Margins / costs G&A expenses fell 28% while R&D rose 22% to support trials. Decrease driven by lower contingent consideration and salaries; increase due to higher clinical trial costs for VIRAGE. ### Capital allocation Cash is allocated to extend runway to Q1 2025 and fund ongoing trials. Focus on clinical trial spend, GMP manufacturing expansion, and limited out‑licensing activities. ### Milestones - **VIRAGE Phase 2b trial (VCN-01)** [on_track]: Enrollment expected to complete first half of 2024. - **Retinoblastoma intravitreal VCN-01 Phase 1 trial follow‑up** [on_track]: Database completion mid‑2024; IND filing anticipated 2024‑25. - **SYN-004 Phase 1b/2a second cohort** [on_track]: Enrollment targeted for Q2 2024. - **Repeated dosing safety of VCN-01** [delivered]: Safety data showed no additional toxicities with second dose. - **Albumin Shield Technology development** [new]: Program advancing to enable more frequent dosing of oncolytic viruses. - **Partnership/out‑licensing discussions** [at_risk]: Partnering environment improving but dependent on data readouts. ### Fears / risks - **Regulatory**: Uncertainty around IND submission timing for retinoblastoma program. - **Clinical**: Efficacy of VCN‑01 yet to be demonstrated; primary survival endpoint readout delayed. - **Financial**: Cash runway extends only to Q1 2025, limiting runway for later-stage trials. - **Market**: Orphan drug designations provide exclusivity but market uptake uncertain. - **Partnership**: Out‑licensing discussions depend on data generation and broader market conditions. - **Execution**: Trial enrollment speed may be affected by patient screening criteria. - **Manufacturing**: Scaling GMP manufacturing for VCN-01 could present operational challenges. - **Competitive**: Other oncolytic virus platforms may compete for similar indications. ### Key quotes > “We have shown that repeated systemic dosing of VCN-01 is feasible from a safety perspective, and we can now focus on whether the repeated dose VCN-01 regimen may lead to improve clinical outcomes for patients.” > “VIRAGE remains on track to complete enrollment in the first-half of 2024.” > “The primary endpoint data, the survival won't read out until next year.” ## Quarter one-liners - **2023 Q4:** Theriva Biologics reports on‑track enrollment for its VCN‑01 VIRAGE trial, delayed IND filing for retinoblastoma, on‑track SYN‑004 cohort, and cash runway into Q1 2025, while highlighting safety feasibility of repeated dosing. - **2023 Q3:** Theriva Biologics reports steady progress on VCN-01, on‑track VIRAGE enrollment for H1‑2024, but data read‑outs won’t arrive until 2025 and regulatory timelines remain uncertain. - **2023 Q2:** Theriva Biologics reports accelerated enrollment in its VCN-01 trials, extended cash runway to Q4 2024, and ongoing development of VCN-11 and SYN-004, while noting UK staffing pressures and IND timing uncertainties. - **2022 Q4:** Theriva Biologics reports ongoing VCN-01 trials, a cash runway into Q3 2024, and aims to complete PDAC enrollment by early 2024 while expanding its albumin‑shield platform. - **2022 Q3:** Theriva Biologics reported accelerated oncology trial progress, secured FDA/Spain clearance for its VIRAGE pancreatic cancer study, advanced SYN-004 and albumin‑shield programs, and said its cash runway extends into Q1 2024. - **2022 Q2:** Synthetic Biologics reports progress on VCN-01, VCN-11 and SYN-004, a $53.5 M cash runway to Q1 2024, and multiple trial initiations slated through 2023. - **2022 Q1:** Synthetic Biologics highlighted its VCN acquisition, announced upcoming Phase 2 trials for VCN-01 in pancreatic cancer and retinoblastoma, and discussed IND filing, IP coverage and funding needs. - **2021 Q4:** Synthetic Biologics highlighted its VCN acquisition, multiple upcoming VCN-01 trials, IND plans for VCN-11, and cash runway to 2023 while noting higher expenses and regulatory uncertainties. ## Theme arcs - **cash runway extension** (improving): Runway extended from 2023 to Q1 2025 across calls - **regulatory uncertainty** (stable): Ongoing FDA and foreign agency queries for retinoblastoma, VCN‑11, and trial designs - **trial enrollment risk** (deteriorating): Leeds brain‑tumor enrollment delayed; broader enrollment critical for VIRAGE - **manufacturing scaling risk** (stable): Repeated concerns about GMP capacity for VCN‑01 and albumin‑shield candidates - **partnership/out‑licensing uncertainty** (stable): Evaluated early, later at‑risk with no deals announced - **data readout timeline** (deteriorating): Key efficacy readouts now pushed to 2025 - **UK staffing constraints** (new): First noted Q2 2023 affecting Leeds trial enrollment ## Fear persistence - **Regulatory uncertainty** [recurring]: Repeated FDA and foreign agency queries across all calls - **Enrollment risk** [recurring]: Consistent concerns about patient accrual in PDAC, brain‑tumor, and other studies - **Funding/cash‑runway risk** [recurring]: Runway extensions noted but limited beyond Q1 2025 - **Manufacturing scaling risk** [recurring]: GMP capacity and quality challenges mentioned multiple times - **Partnership/out‑licensing risk** [recurring]: Uncertainty around deals for SYN‑004, SYN‑020 and other assets - **Competitive risk** [recurring]: Potential emergence of other oncolytic virus programs cited - **Technology risk (albumin shield)** [recurring]: Preclinical status and translation uncertainty highlighted ## Guidance path 2021 Q4:maintained → 2022 Q1:maintained → 2022 Q2:maintained → 2022 Q3:maintained → 2022 Q4:maintained → 2023 Q2:vague → 2023 Q3:maintained → 2023 Q4:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/TOVX`